Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 25%
Hold 25%
Sell 13%
Strong Sell 0%

Bulls say

Gossamer Bio is a clinical-stage biopharmaceutical company with a promising pipeline of therapeutic candidates, particularly Seralutinib which targets the underlying causes of PAH, a serious and currently underserved disease. The company is expecting important data from its PROSERA and FRI studies in mid-2021, which could potentially lead to a new drug application for Seralutinib. The company has a strong management team and strategic partnerships in place, and with a valuation of approximately $2.6 billion, presents an attractive investment opportunity with a potential price target of $10.

Bears say

Gossamer Bio is facing multiple challenges in several key areas, causing a negative outlook on the stock. The company's Phase 3 PROSERA data for seralutinib in PAH fell short of expectations, and the management has noted unusual placebo performance in certain regions. Additionally, the company must restructure its existing convertible debt and secure additional financing for commercialization. Furthermore, adjustments to the company's revenue and market models, coupled with an increased valuation discount rate, have led to a decrease in the target price for the stock.

GOSS has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 8 analysts, GOSS has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.